Form 4: Revance Therapeutics Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Erica Jordan, Chief Commercial Officer of Revance Therapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.
Summary
- Erica Jordan, the Chief Commercial Officer of Revance Therapeutics, sold 2,392 shares of common stock on April 16, 2024.
- The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) granted on April 3, 2023.
- The RSUs vest in equal installments over a four-year period.
- The sale was mandated by Revance Therapeutics' sell-to-cover agreement.
- The shares were sold at a weighted average price of $3.8028.
- Following the transaction, Jordan directly owns 114,864 shares of Revance Therapeutics.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (sell-to-cover) and doesn't indicate any significant positive or negative sentiment.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives and do not necessarily reflect a change in their outlook for the company.
Key Dates
| Date | Description |
|---|---|
| 04/03/2023 | Date of grant for restricted stock units (RSUs) vesting over four years. |
| 04/16/2024 | Date of the stock sale transaction. |
| 04/17/2024 | Date of signature for the Form 4 filing. |
Keywords
Revance Therapeutics, RVNC, Erica Jordan, Chief Commercial Officer, Form 4, Stock Sale, Restricted Stock Units, Tax Withholding, Sell to Cover
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.